WHO ICTRP trial

A Phase 2 Safety and Immunogenicity Study of a Monovalent Pneumococcal Conjugate…

CTIS2023-505154-18-00 · EU Clinical Trials Information System · Recruiting

Key facts

Trial ID CTIS2023-505154-18-00
Public title A Phase 2 Safety and Immunogenicity Study of a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers
Scientific title C4801002 - A Phase 2, Randomized, Open-Label Trial to Describe the Safety and Immunogenicity of A Monovalent Pneumococcal Conjugate Candidate Administered As a 2-Dose Series in Healthy Toddlers 12 Through 15 Months of Age Who Previously Received PCV10 Primary Series in the European Union - C4801002
Primary sponsor Pfizer Inc.
Secondary sponsors Pfizer Europe Ma EEIG
Registry EU Clinical Trials Information System
Recruitment status Recruiting
Study type Interventional clinical trial of medicinal product
Phase Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use - (Phase IV): no
Countries Finland;Poland
Conditions Pneumococcal Infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]-Diseases [C] - Bacterial Infections and Mycoses [C01]
Interventions Product Name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE,Product Code: SUB199854,Pharmaceutical Form: SUSPENSION FOR INJECTION,Other descriptive name: mPnC control,Strength: 2.2µg /…
Registration date Jul 14, 2023
Target size 100
Registry page euclinicaltrials.eu

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations